Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Brenda F, Baker"'
Autor:
Wesley Partridge, Sebastien A. Burel, Annie Ferng, Shuting Xia, T. Jesse Kwoh, Scott P. Henry, Brenda F. Baker
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 4, Pp 575-580 (2023)
Abstract This analysis sought to assess the clinical predictivity of an in vitro assay which utilized the human B‐lymphoma BJAB cell line, for identification of antisense oligonucleotides (ASOs) with the potential to elicit innate immune activation
Externí odkaz:
https://doaj.org/article/c6738881c87b44a086e9231dab0c5d37
Autor:
Nicholas J. Viney, Shuling Guo, Li‐Jung Tai, Brenda F. Baker, Mariam Aghajan, Shiangtung W. Jung, Rosie Z. Yu, Sheri Booten, Heather Murray, Todd Machemer, Sebastien Burel, Sue Murray, Gustavo Buchele, Sotirios Tsimikas, Eugene Schneider, Richard S. Geary, Merrill D. Benson, Brett P. Monia
Publikováno v:
ESC Heart Failure, Vol 8, Iss 1, Pp 652-661 (2021)
Abstract Aims Amyloidogenic transthyretin (ATTR) amyloidosis is a fatal disease characterized by progressive cardiomyopathy and/or polyneuropathy. AKCEA‐TTR‐LRx (ION‐682884) is a ligand‐conjugated antisense drug designed for receptor‐mediat
Externí odkaz:
https://doaj.org/article/3297462a8e6e4c1081fbb6040b37c72e
Autor:
Brenda F. Baker, Shuting Xia, Wesley Partridge, T. Jesse Kwoh, Sotirios Tsimikas, Sanjay Bhanot, Richard S. Geary
Publikováno v:
Nucleic Acid Therapeutics. 33:72-80
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::54dc571f4f0996da54a23f710d864e2f
https://doi.org/10.1089/nat.2022.0044
https://doi.org/10.1089/nat.2022.0044
Autor:
Wesley Partridge, Sebastien A. Burel, Annie Ferng, Shuting Xia, T. Jesse Kwoh, Scott P. Henry, Brenda F. Baker
Publikováno v:
Clinical and Translational Science. 16:575-580
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a7f81cf1eece4016b888ad0783697dd
https://doi.org/10.1111/cts.13476
https://doi.org/10.1111/cts.13476
Autor:
Thomas H. Brannagan, John L. Berk, Julian D. Gillmore, Mathew S. Maurer, Márcia Waddington‐Cruz, Marianna Fontana, Ahmad Masri, Laura Obici, Michela Brambatti, Brenda F. Baker, Lisa A. Hannan, Gustavo Buchele, Nick J. Viney, Teresa Coelho, Jose Nativi‐Nicolau
Publikováno v:
Journal of the Peripheral Nervous System. 27:228-237
Transthyretin-mediated amyloidosis (ATTR) is a rare, under-recognized, progressively debilitating, fatal disease caused by the aggregation and extracellular deposition of amyloid transthyretin (TTR) fibrils in multiple organs and tissues throughout t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::decd1173bd131184ac6c363ff1247ca9
https://doi.org/10.1111/jns.12519
https://doi.org/10.1111/jns.12519
Autor:
Brenda F. Baker, Shuting Xia, Wesley Partridge, Richard S. Geary, Sanjay Bhanot, T. Jesse Kwoh
Publikováno v:
Nucleic Acid Therapeutics
The development process of antisense oligonucleotides (ASOs) as therapeutic agents in humans has advanced through the implementation of chemical compound modifications as well as increasingly sophisticated toxicological preclinical screening techniqu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a15be03ddcace5a4a9c8c879eb0520
https://doi.org/10.1089/nat.2020.0917
https://doi.org/10.1089/nat.2020.0917
Autor:
Brenda F, Baker, Shuting, Xia, Wesley, Partridge, T Jesse, Kwoh, Sotirios, Tsimikas, Sanjay, Bhanot, Richard S, Geary
Publikováno v:
Nucleic acid therapeutics.
Receptor-mediated delivery of an antisense oligonucleotide (ASO) using the ligand-conjugated antisense technology is establishing a new benchmark for antisense therapeutics. The triantennary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1cac4ff6aa3549f8c0528a32a24803c8
https://pubmed.ncbi.nlm.nih.gov/36454263
https://pubmed.ncbi.nlm.nih.gov/36454263
Autor:
Sebastien A. Burel, Todd Machemer, Brenda F. Baker, T. Jesse Kwoh, Suzanne Paz, Husam Younis, Scott P. Henry
Publikováno v:
Nucleic acid therapeutics. 32(6)
A human peripheral blood mononuclear cell (PBMC)-based assay was developed to identify antisense oligonucleotide (ASO) with the potential to activate a cellular innate immune response outside of an acceptable level. The development of this assay was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7850a496fa46739046720e393abb6b4
https://pubmed.ncbi.nlm.nih.gov/35976085
https://pubmed.ncbi.nlm.nih.gov/35976085
Publikováno v:
Nature Reviews Drug Discovery. 20:427-453
Antisense technology is now beginning to deliver on its promise to treat diseases by targeting RNA. Nine single-stranded antisense oligonucleotide (ASO) drugs representing four chemical classes, two mechanisms of action and four routes of administrat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1bdc3d789a7b40f78c4d2eb87bb9ee51
https://doi.org/10.1038/s41573-021-00162-z
https://doi.org/10.1038/s41573-021-00162-z
Autor:
Lauré M. Fijen, Marc A. Riedl, Laura Bordone, Jonathan A. Bernstein, Jason Raasch, Raffi Tachdjian, Timothy Craig, William R. Lumry, Michael E. Manning, Veronica J. Alexander, Kenneth B. Newman, Alexey Revenko, Brenda F. Baker, Charvi Nanavati, A. Robert MacLeod, Eugene Schneider, Danny M. Cohn
Publikováno v:
The New England journal of medicine, 386(11), 1026-1033. Massachussetts Medical Society
BACKGROUND: Hereditary angioedema is characterized by recurrent and unpredictable swellings that are disabling and potentially fatal. Selective inhibition of plasma prekallikrein production by antisense oligonucleotide treatment (donidalorsen) may re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a16b30232910dd9e1208365ce91cad3
https://pubmed.ncbi.nlm.nih.gov/35294818
https://pubmed.ncbi.nlm.nih.gov/35294818